pyrazines has been researched along with Cardiomyopathies, Primary in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, H; Jiang, F; Wang, S; Wu, K; Xiao, B; Yin, K; Zhang, M; Zhou, Z | 1 |
| Franz, WM; Hiergeist, L; Kozlik-Feldmann, R; Mechea, A; Netz, H; Theisen, D; Zaruba, MM | 1 |
| Abar, F; Dibb, J; Dibb, W; Frires, R; Heitner, SB; Kovacsovics, T; Maziarz, RT; Meyers, G; Perez-Avraham, G; Scott, EC; Smith, SD; Stentz, A | 1 |
| Bridoux, F; Comenzo, RL; Decaux, O; Gillmore, J; Hari, P; Hawkins, PN; Jaccard, A; Lavergne, D; Lazaro, E; Macro, M; Mercie, P; Mohty, D; Morel, P; Pellegrin, JL; Roussel, M; Venner, CP; Wechalekar, AD | 1 |
| Merlini, G; Palladini, G | 1 |
| Haddad, T; Lopez-Cepero, M; Rolfe, M; Weston, M | 1 |
| Alloway, RR; Eckman, PM; Kim, Y; Maurer, D; Thorsgard, M; Woodle, ES | 1 |
| Abraham, J; Bridoux, F; Delbès, S; Desport, E; Fermand, JP; Jaccard, A; Lacotte-Thierry, L; Moumas, E; Touchard, G | 1 |
| Alter, M; Chaykovska, L; Fuchs, H; Heiden, S; Hocher, B; Klein, T; Rahnenführer, J; Runge, F; von Websky, K | 1 |
| Gatt, ME; Palladini, G | 1 |
| Matoba, Y; Matsui, S; Matsumori, A; Sasayama, S; Uchida, A | 1 |
| Becker, LC; Feldman, AM; Kasper, EK; Kass, DA; Van Anden, E; White, WB | 1 |
2 review(s) available for pyrazines and Cardiomyopathies, Primary
| Article | Year |
|---|---|
[Current treatment of AL amyloidosis].
Topics: Amyloid; Amyloidosis; Biomarkers; Boronic Acids; Bortezomib; Cardiomyopathies; Consensus Development Conferences as Topic; Dexamethasone; Drug Therapy, Combination; Heart Transplantation; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Kidney Failure, Chronic; Kidney Transplantation; Lenalidomide; Melphalan; Natriuretic Peptide, Brain; Paraproteinemias; Paraproteins; Peptide Fragments; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Renal Dialysis; Thalidomide | 2011 |
Light chain amyloidosis 2012: a new era.
Topics: Alkylating Agents; Amyloid; Amyloidosis; Biomarkers; Boronic Acids; Bortezomib; Cardiomyopathies; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Forecasting; Humans; Immunoglobulin Light Chains; Immunologic Factors; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Pyrazines; Risk; Severity of Illness Index; Stem Cell Transplantation; Troponin C; Troponin T | 2013 |
1 trial(s) available for pyrazines and Cardiomyopathies, Primary
| Article | Year |
|---|---|
Dose dependence of chronic positive inotropic effect of vesnarinone in patients with congestive heart failure due to idiopathic or ischemic cardiomyopathy.
Topics: Administration, Oral; Cardiomyopathies; Cardiotonic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Heart Failure; Hemodynamics; Humans; Pyrazines; Quinolines; Regression Analysis; Ventricular Function | 1996 |
9 other study(ies) available for pyrazines and Cardiomyopathies, Primary
| Article | Year |
|---|---|
The mechanosensitive Piezo1 channel mediates heart mechano-chemo transduction.
Topics: Animals; Arrhythmias, Cardiac; Calcium; Calcium Signaling; Cardiomyopathies; Gene Deletion; Heart Failure; Heart Function Tests; Homeostasis; Ion Channels; Mechanotransduction, Cellular; Mice, Knockout; Myocardium; Myocytes, Cardiac; Organ Specificity; Pyrazines; Reactive Oxygen Species; Thiadiazoles; Up-Regulation | 2021 |
First treatment of a child suffering from severe ischemic cardiomyopathy with G-CSF and sitagliptin.
Topics: Cardiomyopathies; Combined Modality Therapy; Dipeptidyl-Peptidase IV Inhibitors; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myocardial Ischemia; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
Topics: Adult; Aged; Amyloidogenic Proteins; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiomyopathies; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Kidney Diseases; Lenalidomide; Male; Melphalan; Middle Aged; Myeloablative Agonists; Proteasome Inhibitors; Pyrazines; Remission Induction; Retrospective Studies; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2014 |
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Cardiomyopathies; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Protein Aggregates; Pyrazines; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2014 |
Treating advanced cardiac damage in light chain amyloidosis: still an unmet need.
Topics: Amyloidosis; Boronic Acids; Bortezomib; Cardiomyopathies; Cyclophosphamide; Dexamethasone; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Pyrazines | 2014 |
Desensitization protocol using bortezomib for highly sensitized patients awaiting heart or lung transplants.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Cardiomyopathies; Desensitization, Immunologic; Female; Heart Transplantation; Humans; Immunoglobulins, Intravenous; Isoantibodies; Lung Transplantation; Male; Middle Aged; Plasmapheresis; Protease Inhibitors; Pyrazines; Transfusion Reaction; Waiting Lists | 2009 |
Bortezomib for refractory antibody-mediated cardiac allograft rejection.
Topics: Aged; Biopsy; Boronic Acids; Bortezomib; Cardiomyopathies; Female; Flow Cytometry; Graft Rejection; Heart Transplantation; Humans; Isoantibodies; Protease Inhibitors; Pyrazines; Transplantation, Homologous; Treatment Outcome | 2009 |
Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.
Topics: Animals; Area Under Curve; Cardiomyopathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Gene Expression Regulation; Glomerular Filtration Rate; Glucagon-Like Peptide 1; Heart; Humans; Kidney Failure, Chronic; Linagliptin; Myocardium; Natriuretic Peptide, Brain; Nephrectomy; Piperidines; Purines; Pyrazines; Quinazolines; Rats; Reverse Transcriptase Polymerase Chain Reaction; Sitagliptin Phosphate; Triazoles; Uracil; Uremia | 2011 |
Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production.
Topics: Amrinone; Animals; Cardiomyopathies; Cardiovirus Infections; Encephalomyocarditis virus; Female; Immunosuppressive Agents; Killer Cells, Natural; Male; Mice; Mice, Inbred DBA; Mice, Inbred Strains; Myocardium; Pregnancy; Pyrazines; Quinolines; Time Factors; Tumor Necrosis Factor-alpha | 1994 |